Skip to content

REFERENCE FILE

Liraglutide

Examine the reference details alongside the questions and dated sources.

Reference details

Status as of

Regulatory category
Approved product
Evidence category
Randomized evidence
Mechanism
Activates the GLP-1 receptor.
Evidence
Randomized trials.
Limitations
Check other products separately.
Safety
The label warns about severe gastrointestinal reactions.
Formulation and route
Subcutaneous injection.
Approval scope
Saxenda: weight management for eligible patients.

READING NOTES

Questions for a closer look

Use a liraglutide paper to separate questions about authorship from questions about the argument. Read the affiliations and disclosures, then select a conclusion and trace its supporting measurement, comparison and reasoning. Keep a note about each author's stated role beside, rather than in place of, that reconstruction. Try a counterfactual reading: if the institutional names were hidden, which part of the argument would still need checking? Restore the names and ask whether they suggest a specific additional question about responsibility or access to records. The result should be a focused inquiry, not a verdict inferred from an affiliation.

Questions to investigate

  1. Which stated role connects an author to the analysis being discussed?
  2. What would I still need to verify if the affiliations were hidden?
  3. Does a disclosure suggest a specific question about responsibility or access?

Sources for this file

  1. SAXENDANLM · Checked

MED CONSUMER WATCH · RESEARCH

Read the evidence behind the question.

Browse reference files or follow a study analysis from its question to its limitations.